Leah Kuntz

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

Explore essential insights and best practices in geriatric psychiatry in our July theme! Submit your insights, tips, and case studies centered on healthy aging for older adults.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Check out the pipeline updates from June!

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

Christine Yu Moutier, MD, the chief medical officer of the AFSP, speaks about the impact of losing LGBTQ+ tailored crisis support via 988, and strategies to better support vulnerable youth.

Stay informed with this week's highlights, including more on the clozapine REMS, the termination of the 988 LGBTQ+ specific services, and the intersection of sex and psychiatry!

LGBTQ+ youth face increased suicide risks as vital support services are cut, prompting urgent calls for Congress to reverse this dangerous decision.

Ecopipam shows promise as a safe, effective treatment for Tourette syndrome in children and adolescents, significantly reducing tic severity and improving quality of life.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

US Senators have reintroduced The Access to Prescription Digital Therapeutics Act to increase access to prescription digital therapeutics and decrease barriers to care.

The government has always played an important role in health care. Recent changes, however, are actively altering the practice of medicine and are posed to have a deep and lasting psychiatric impact on patients. Learn more here.

Championing diverse voices: check out our June theme! We want to hear about your insights, tips, and case studies.

Discover key insights from the APA Annual Meeting, highlighting advancements in lifestyle psychiatry, ADHD treatment, and innovative suicide prevention models.

Check out the pipeline updates from May!

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.